Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Risdiplam in Hepatic Impairment
NCT03920865Phase 1Completed
- Sponsor
- Roche
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of risdiplam in spinal muscular atrophy (SMA) (4 arms), sponsored by Roche. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measurable Concentration and 1 more. Started May 2019; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT03920865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920865.